Key Record Dates
| ClinicalTrials.gov Identifier: | NCT03725059 |
|---|---|
| Brief Title: | Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) |
| First Submitted : | October 29, 2018 |
| First Submitted that Met QC Criteria : | October 29, 2018 |
| First Posted : | October 30, 2018 |
| Last Update Submitted that Met QC Criteria : | July 27, 2022 |
| Last Update Posted : | July 28, 2022 |